Legacy Advisors LLC Takes $65,000 Position in Kura Oncology Inc (KURA)
Legacy Advisors LLC acquired a new position in shares of Kura Oncology Inc (NASDAQ:KURA) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 3,900 shares of the company’s stock, valued at approximately $65,000.
Other hedge funds have also recently modified their holdings of the company. Great West Life Assurance Co. Can acquired a new position in Kura Oncology during the fourth quarter worth $62,000. Legal & General Group Plc increased its position in Kura Oncology by 21.7% during the fourth quarter. Legal & General Group Plc now owns 5,175 shares of the company’s stock worth $73,000 after buying an additional 923 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its position in Kura Oncology by 403.3% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 9,638 shares of the company’s stock worth $135,000 after buying an additional 7,723 shares in the last quarter. BlueMountain Capital Management LLC increased its position in Kura Oncology by 2,315.9% during the third quarter. BlueMountain Capital Management LLC now owns 10,775 shares of the company’s stock worth $189,000 after buying an additional 10,329 shares in the last quarter. Finally, Trexquant Investment LP purchased a new position in Kura Oncology during the third quarter worth $217,000. 84.95% of the stock is owned by hedge funds and other institutional investors.
Kura Oncology stock opened at $15.51 on Wednesday. The company has a quick ratio of 13.31, a current ratio of 13.31 and a debt-to-equity ratio of 0.05. The firm has a market cap of $617.59 million, a price-to-earnings ratio of -9.02 and a beta of 2.91. Kura Oncology Inc has a fifty-two week low of $10.20 and a fifty-two week high of $22.00.
Several equities analysts have weighed in on KURA shares. ValuEngine downgraded Kura Oncology from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 24th. BidaskClub raised Kura Oncology from a “hold” rating to a “buy” rating in a research report on Friday, December 21st. Zacks Investment Research downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research report on Tuesday, January 8th. Finally, Oppenheimer reissued a “buy” rating on shares of Kura Oncology in a research report on Tuesday, March 19th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Kura Oncology has a consensus rating of “Buy” and an average target price of $28.20.
Kura Oncology Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Recommended Story: How prevalent are 12b-1 fees?
Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology Inc (NASDAQ:KURA).
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.